No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 3.6x · 10Y median 162.4x · 3rd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 20
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T18:28:25.742Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T18:28:25.742Z. Latest historical point 2025-05-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T18:28:25.742Z. Latest historical point 2025-05-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T18:28:25.742Z. Latest historical point 2025-05-14.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T18:28:25.742Z. Latest historical point 2025-05-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T18:28:25.742Z. Latest historical point 2025-05-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for ARS Pharmaceuticals, Inc. (SPRY) stock was $4.28 as of Oct 6, 2026, 2:25 PM EDT, down 0.21% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -58.2% · 3-year avg +2.5%/yr · 5-year avg -16.4%/yr
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology.
Biotechnology · San Diego, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.33
Revenue Est.
$42.84M
Last Quarter Results
EPS
$-0.63
vs Estimate
$-0.49
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SPRY | $425.13M | $4.28 | -0.21% | -58.22% | -16.35% | N/A | N/A |
| 2TLRY | $426.64M | $3.81 | +2.55% | -76.88% | -49.30% | N/A | vs SPRY |
| 3PRTA | $420.94M | $8.04 | -2.78% | -16.56% | -35.08% | -18.37% | vs SPRY |
| 4EDIT | $430.46M | $2.81 | +0.54% | -28.71% | -40.76% | -15.75% | vs SPRY |
| 5NEO | $431.16M | $16.78 | -12.28% | +109.48% | -15.14% | +8.90% | vs SPRY |
| 6MPLT | $418.85M | $9.87 | +6.42% | N/A | N/A | N/A | vs SPRY |
forward FY estimate
N/A
$33.66M
vs Estimate
$31.32M
Consensus Rating
Based on 4 analysts
Average Price Target
$22.50
+425.6% upside
Low
$15.00
Current
$4.28
High
$30.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.35 | $-0.30 | $-0.25 | 2 |
| Quarter ending Dec 2026 | $-0.34 | $-0.29 | $-0.23 | 2 |
| Quarter ending Mar 2027 | $-0.41 | $-0.35 | $-0.33 | 1 |
| Quarter ending Jun 2027 | $-0.27 | $-0.23 | $-0.22 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.90 | $-1.78 | $-1.67 | 3 |
| FY 2027 | $-0.92 | $-0.81 | $-0.64 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $41.41M | $42.84M | $44.27M | 3 |
| Quarter ending Dec 2026 | $30.76M | $30.80M | $30.82M | 3 |
| Quarter ending Mar 2027 | $26.75M | $27.94M | $31.30M | 1 |
| Quarter ending Jun 2027 | $42.97M | $44.88M | $50.27M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $128.47M | $129.91M | $131.35M | 3 |
| FY 2027 | $174.99M | $190.61M | $206.24M | 3 |
